AstraZeneca's gene-silencing drug trial disappoints; co-treatment may explain setback

A high-profile study of AstraZeneca and Ionis Pharmaceuticals' Wainua for heart disease failed unexpectedly, according to the trial's lead investigator. The failure may be linked to patients concurrently taking a Pfizer medication for the same condition, which could have confounded results. The outcome raises questions about the drug's future development path.

The unexpected failure of Wainua, a gene-silencing therapy developed jointly by AstraZeneca and Ionis Pharmaceuticals, has cast doubt on its potential as a heart disease treatment. The trial's lead investigator disclosed that the study did not meet its intended goals, a surprising outcome given the drug's earlier promise.

A key complication emerged during analysis: many patients were simultaneously taking a Pfizer medication for the same condition. This co-treatment may have masked or altered Wainua's effects, making it difficult to isolate the drug's true performance. The finding raises significant questions about how to interpret the trial and whether future studies will need to account for concurrent therapies.